November 2018, Volume 4, Issue 13

November 2018

Volume 4, Issue 13

This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.

Table of Contents

November 2018 Issue

Draining the Email Swamp

Thursday, November 1st, 2018
On a typical weekday, I receive 200 emails and send 40. Unless you, dear reader, are the taciturn Seattle hematologist who hasn’t responded to...

November 2018 Issue

Lili Yang Wins $1.4 Million CIRM Quest Discovery Grant, and more

Thursday, November 1st, 2018
Remembering Thomas Michael Przybysz (1951-2018)  Thomas Michael Przybysz, MD, an oncologist, passed away on July 19, 2018, at the age of 66. After serving in the...

Nancy Berliner Named Next Editor-in-Chief of Blood, and more

Thursday, November 1st, 2018
ASH Launches New Sickle Cell Disease Clinical Trials Network  ASH has announced the launch of a clinical trials network in sickle cell disease (SCD) to...

November 2018 Issue

Who Pays What, and Why?

Thursday, November 1st, 2018
From R&D to PBMs, a look at the U.S. approach to drug pricing  When it comes to setting drug prices, the U.S. is singular in...

Rethinking Burnout

Thursday, November 1st, 2018
Will solving physician burnout require sweeping changes to the U.S. health-care system?  About 15 years ago, during the first year of his fellowship, Tait Shanafelt,...

Pulling Back the Curtain: Richard W. Childs, MD

Thursday, November 1st, 2018
In this edition, Richard W. Childs, MD, talks about his accomplishments in immunotherapy, his role in the response to the 2014 West Africa Ebola...

November 2018 Issue

How I Treat In Brief: Managing Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Thursday, November 1st, 2018
Jennifer A. Woyach, MD, associate professor at the Ohio State University Comprehensive Cancer Center, wrote about her strategy for the management of patients with...

How to Treat Anemia in a Patient Who Refuses Transfusions for Religious Reasons

Thursday, November 1st, 2018
This month, Neil A. Zakai, MD, discusses how to treat anemia in a patient who refuses packed red blood cells. And don't forget to check out...

How to Treat Anemia in a Patient Who Refuses Transfusions for Religious Reasons

Thursday, November 1st, 2018
Here’s how readers responded to a You Make the Call question about a Jehovah's Witness patient with stage IV uterine cancer, a uterine abscess,...

November 2018 Issue

FDA Approves New Treatment for Hemophilia

Thursday, November 1st, 2018
The U.S. Food and Drug Administration (FDA) approved BAY94-9027, or antihemophilic factor (recombinant), PEGylated-aucl, for the prophylactic treatment of adults and adolescents (≥12 years)...

Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis

Thursday, November 1st, 2018
Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...

FDA Approves Ibrutinib Combo for Waldenström Macroglobulinemia

Thursday, November 1st, 2018
The U.S. Food and Drug Administration (FDA) approved ibrutinib, in combination with rituximab, for the treatment of adult patients with Waldenström macroglobulinemia (WM). In...
WIB_icon

Pre-emptive Rituximab Prevents Long-Term Relapses in Immune-Mediated TTP

Thursday, November 1st, 2018
Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have persistent, severe ADAMTS13 deficiency have a high likelihood of relapse, but pre-emptive treatment with rituximab...

Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety

Thursday, November 1st, 2018
Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...

Elephants’ “Zombie Gene” May Prevent Cancer

Thursday, November 1st, 2018
Researchers have identified a gene that appears to solve the mystery of why elephants – who should be at a greater risk of developing...
WIB_icon

MRD Negativity Measured Via Next-Generation Sequencing Predicts Long-Term Survival in Myeloma

Thursday, November 1st, 2018
Measuring minimal residual disease (MRD) status using next-generation sequencing (NGS) represented a prognostic biomarker for survival in patients with multiple myeloma (MM), according to...

Post-Transplant Gene Mutations Predict Risk for MDS Progression

Thursday, November 1st, 2018
Sequencing bone marrow samples early after patients with myelodysplastic syndromes (MDS) have undergone allogeneic hematopoietic cell transplantation (AHCT) could help identify patients who are...

Oncology Community Reacts to Medicare Advantage’s “Step Therapy” Decision

Thursday, November 1st, 2018
In early August 2018, the Centers for Medicare and Medicaid Services (CMS) announced it will allow Medicare Advantage plans to implement “step therapy” for...
WIB_icon

Next-Generation Sequencing MRD Assessment Valuable Tool in AML Management

Thursday, November 1st, 2018
Assessing minimal residual disease (MRD) using next-generation sequencing (NGS) in patients with acute myeloid leukemia (AML) prior to undergoing allogeneic hematopoietic cell transplantation (alloHCT)...
WIB_icon

Risk of Thrombosis in Patients With Cancer and Implanted Ports

Thursday, November 1st, 2018
Although patients with solid-tumor cancers and implanted ports have a high risk for venous thromboembolism (VTE), guidelines advise against routine thromboprophylaxis, given the wide...

Rivaroxaban Fails to Prevent VTE and VTE-Related Mortality After Hospital Discharge

Thursday, November 1st, 2018
Patients hospitalized for an acute medical illness are at an increased risk for developing venous thromboembolism (VTE) in the six weeks after discharge, but...

Rituximab Plus Lenalidomide Noninferior to Chemotherapy in Treatment-Naïve Follicular Lymphoma

Thursday, November 1st, 2018
Treatment with the chemotherapy-free combination of rituximab and the immunomodulatory agent lenalidomide (R2) was noninferior to the combination of rituximab and chemotherapy (R-chemo) in...

Theranos Shutting Down Amid Fraud Allegations

Thursday, November 1st, 2018
In a letter to investors, the CEO of Theranos announced that the bloodtesting company is preparing to shut down. Theranos has faced a U.S....
WIB_icon

Examining Hospice Use Among Transfusion-Dependent Patients With Leukemia

Thursday, November 1st, 2018
Since 2001, more patients with leukemia are receiving hospice services, which has been associated with improved quality of life, according to an analysis published...

SHARE